ロード中...
PS2-11: Validation of KRAS Mutation Testing Across Five Certified Laboratories
KRAS mutation testing helps oncologists decide whether patients diagnosed with metastatic colorectal cancer (CRC) should be treated with epidermal growth factor receptor (EGFR) inhibitors. These drugs block the EGFR signaling pathway in tumor cells, and thus can slow tumor progression. Mutated KRAS...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Marshfield Clinic
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3251394/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3121/cmr.2011.1020.ps2-11 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|